QTTB
Q32 Bio IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$80.02M
P/E Ratio
2.26
EPS
$2.42
Beta
-1.02
52W High
$8.04
52W Low
$1.34
50-Day MA
$5.14
200-Day MA
$3.12
Dividend Yield
—
Profit Margin
55.50%
Forward P/E
—
PEG Ratio
—
About Q32 Bio Inc
Q32 Bio Inc. is a pioneering biotechnology firm focused on developing innovative antibody-based therapies to address autoimmune diseases and enhance immune responses. Utilizing its proprietary technology platform, the company is advancing a robust pipeline of treatments designed to restore immune system balance. Backed by a seasoned management team and strategic collaborations, Q32 Bio is well-positioned to leverage its scientific expertise to meet significant unmet medical needs, thereby driving transformative advancements in healthcare and creating value for shareholders through sustained research and development initiatives.
Fundamentals
| Revenue (TTM) | $53.74M |
| Gross Profit (TTM) | $34.58M |
| EBITDA | $17.29M |
| Operating Margin | 85.40% |
| Return on Equity | 125.10% |
| Return on Assets | 13.70% |
| Revenue/Share (TTM) | $4.37 |
| Book Value | $3.27 |
| Price-to-Book | 2.22 |
| Price-to-Sales (TTM) | 1.49 |
| EV/Revenue | 1.124 |
| EV/EBITDA | 1.93 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $14.63M |
| Float | $6.33M |
| % Insiders | 6.52% |
| % Institutions | 65.72% |
Analyst Ratings
Consensus ($14.33 target)
2
Buy1
HoldData last updated: 4/9/2026